Description
Anti-IFNγ Antibody, Non-Fucosylated (BioBet-053ZP) is a human monoclonal IgG1 antibody against IFNγ. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Primary hemophagocytic lymphohistiocytosis
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced IFNγ antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Full Name
interferon gamma.
Background
Produced by lymphocytes activated by specific antigens or mitogens. IFNgamma, in addition to having antiviral activity, has important immunoregulatory functions. It is a potent activator of macrophages, it has antiproliferative effects on transformed cells and it can potentiate the antiviral and antitumor effects of the type I interferons.
Alternative Names
IFNγ, IFN-gamma
Cellular Localization
Extracellular region or secreted
Involvement in Disease
Diseases associated with IFNG include Hepatitis C Virus and Tuberous Sclerosis 2.
Related Pathways
Its related pathways are Folate Metabolism and Tuberculosis.
Function
Produced by lymphocytes activated by specific antigens or mitogens. In addition to the antiviral activity of ifn-gamma, it also has important immune regulation functions. It is a strong activator of macrophages, has an anti-proliferation effect on transformed cells, and can enhance the antiviral and antitumor effects of type I interferon.
Post-translational modifications
Proteolytic processing produces C-terminal heterogeneity, with proteins ending alternatively at Gly-150, Met-157 or Gly-161.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Clone
BioBet-053ZP
Description
Emapalumab, trade name Gamifant, also known as NI-0501, is a fully human monoclonal antibody that targets interferon gamma. Emapalumab was developed by NovImmune SA and Sobi and approved on November 20, 2018 for the treatment of hemophagocytic lymphohistiocytosis (HLH).
Antibody Indication
Progressive, refractory, primary intolerance with conventional therapy
Recurrent Hemophagocytic Lymphohistiocytosis
